Histologic Response of High-Grade Nonmetastatic Osteosarcoma of the Extremity to Chemotherapy
- 1 May 2001
- journal article
- research article
- Published by Wolters Kluwer Health
- Vol. 386 (386) , 186-196
- https://doi.org/10.1097/00003086-200105000-00024
Abstract
In 510 patients with osteosarcoma of the extremity treated at the authors’ institute between March 1983 and June 1995 with different regimens of neoadjuvant chemotherapy, factors that influenced the histologic response were investigated. The rate of total necrosis was not related to the patients’ gender, age, site, size of tumor, serum of alkaline phosphatase values, or route of cisplatin administration. The histologic response significantly and independently correlated with the number of drugs administered before surgery and with the histologic subtype of the tumor. According to the number of drugs used, the percentage of total necrosis was 31% for a four-drug regimen, 18% for a three-drug regimen, and only 1.5% for a two-drug regimen. According to the histologic type, the rates of total necrosis were 41% for telangiectatic tumors, 36% for fibroblastic tumors, 15% for osteoblastic tumors, and 3% for chondroblastic tumors. The authors concluded that in neoadjuvant therapy of osteosarcoma, the histologic response to preoperative treatment, which correlates with prognosis, depends on the effectiveness of the chemotherapy regimen and on some features intrin-sically inherent to the tumor. These data should be considered when selecting the type of treatment (adjuvant or neoadjuvant) and the combinations of drugs to be used in preoperative treatment of patients with osteosarcoma.Keywords
This publication has 22 references indexed in Scilit:
- Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbsPublished by Elsevier ,1998
- Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.Journal of Clinical Oncology, 1998
- Predictive factors for local recurrence in osteosarcoma 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapyActa Orthopaedica, 1998
- Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th StudyActa Oncologica, 1998
- Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicinCancer, 1993
- Influence of Adriamycin Dose in the Outcome of Patients with Osteosarcoma Treated with Multidrug Neoadjuvant Chemotherapy: Results of Two Sequential StudiesJournal of Chemotherapy, 1993
- A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.Journal of Clinical Oncology, 1992
- Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatinCancer, 1990
- Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescentsZeitschrift für Krebsforschung und Klinische Onkologie, 1987
- The pathologist's role in the diagnosis and treatment of osteosarcoma in childrenHuman Pathology, 1984